Poolbeg Pharma in-licencing exciting programmes ready for big pharma (Interview)

Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss the in-licencing of a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.

Jeremy tells us more about this new deal, explains the terms, what being at a late pre-clinical stage means and explains the ultimate plan for this asset.

Poolbeg Pharma (LON: POLB) is a clinical stage infectious disease pharmaceutical company, with a clinical model which enables them to develop multiple products faster and more cost effectively than a traditional biotech model.

You might also enjoy reading  Poolbeg Pharma OneThree Biotech completes build and optimisation of RSV AI model
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma plc

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp